Clinical trials: Risk Assessment
RSV Infection
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
This was a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who were at high risk for complications…
- Trial name
- RSVHR (NCT05568706)
- Testing
- EDP-938
- Where
- 84 sites in United States, Argentina and 10 more
- Volunteers
- 187 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
HIV
Evaluating a Structural and Behavioral HIV Risk Reduction Program for Black Men
The purpose of this study is to evaluate the effectiveness of the Making Employment Needs (MEN) Count intervention, an HIV intervention and prevention program for heterosexual Black men.
- Trial name
- MENCount (NCT01694121)
- Testing
- MEN Count, Comparison
- Where
- United States
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Pulmonary Disease, Chronic Obstructive
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
The aim of this First Time in Patient study is to obtain initial information on the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of repeat daily administration of danirixin in subjects with…
- Trial name
- NCT02130193
- Testing
- Danirixin
- Where
- 16 sites in United States, Germany
- Volunteers
- 102 people
- Sponsor
- GlaxoSmithKline
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT03279250
- Testing
- Abiraterone Acetate, Apalutamide, Gonadotropin-releasing Hormone Analog
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- M.D. Anderson Cancer Center
COVID-19
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with…
- Trial name
- Mir-Age (NCT04393038)
- Testing
- ABX464
- Where
- 30 sites in Belgium, Brazil and 6 more
- Volunteers
- 509 people
- Sponsor
- Abivax S.A.
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Keratolysis
Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
This is a phase I/II prospective, randomized, multi-center, double-masked, vehicle-controlled clinical trial evaluating the safety and efficacy of corneal collagen cross-linking the keratoprosthesis carrier tissue in subjects who…
- Trial name
- NCT02863809
- Testing
- Riboflavin, Dextran, UVA Light Source
- Where
- 13 sites in United States
- Volunteers
- 76 people
- Sponsor
- Joseph B. Ciolino, MD
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.
- Trial name
- PRIMROSE (NCT04978337)
- Testing
- Rilematovir
- Where
- 86 sites in United States, Argentina and 12 more
- Volunteers
- 5 people
- Sponsor
- Janssen Research & Development, LLC
Hypertension, Cardiovascular Diseases
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks.
- Trial name
- NCT00904371
- Where
- 36 sites in Slovenia
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Gastric Ulcer
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at…
- Trial name
- NCT00527787
- Testing
- PN400 (VIMOVO), Naproxen
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- POZEN
Alzheimers Disease
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD.
- Trial name
- SKYLINE (NCT05256134)
- Testing
- Gantenerumab
- Where
- 63 sites in United States, Argentina and 8 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
COVID-19
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
- Trial name
- SPRINT (NCT05616728)
- Testing
- EDP-235
- Where
- 23 sites in United States, Romania
- Volunteers
- 231 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Breast Cancer
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Zoledronate may delay or prevent bone marrow metastases in patients with breast cancer. PURPOSE: This phase II trial is studying how well zoledronate works in treating bone marrow micrometastases in women with stage I…
- Trial name
- NCT00295867
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Type 2, Cardiovascular Diseases
CANVAS - CANagliflozin cardioVascular Assessment Study
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE).
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
- Trial name
- CANVAS (NCT01032629)
- Testing
- Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
- Where
- 305 sites in United States, Argentina and 23 more
- Volunteers
- 4,330 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes, Metabolic Diseases
The Fasting II Study
This study will determine whether an intensive fasting protocol alters hemoglobin A1c measurements or other markers of metabolic and cardiovascular risk by performing a 5-week clinical trial of fasting among 12 pre-diabetic…
- Trial name
- NCT01792986
- Testing
- water-only 24-hour fasting once per week for 6 weeks
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Intermountain Health Care, Inc.
Hyperlipidemia
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
- Trial name
- SPIRE-HR (NCT01968954)
- Testing
- Bococizumab (PF-04950615;RN316)
- Where
- 103 sites in United States, Australia and 7 more
- Volunteers
- 711 people
- Sponsor
- Pfizer
Dyslipidemia
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).
- Trial name
- FOURIER OLE (NCT02867813)
- Testing
- Evolocumab
- Where
- 198 sites in United States, Czechia and 5 more
- Volunteers
- 5,035 people
- Sponsor
- Amgen